Review Article

You have full text access to this OnlineOpen article

Pulmonary neuroendocrine/carcinoid tumors

A review article

  1. Erin M. Bertino MD1,
  2. Patricia D. Confer BS, CTR2,
  3. Jorge E. Colonna MD3,
  4. Patrick Ross MD, PhD4,
  5. Gregory A. Otterson MD1,†,*

Article first published online: 26 JUN 2009

DOI: 10.1002/cncr.24498

Issue

Cancer

Cancer

Volume 115, Issue 19, pages 4434–4441, 1 October 2009

Additional Information

How to Cite

Bertino, E. M., Confer, P. D., Colonna, J. E., Ross, P. and Otterson, G. A. (2009), Pulmonary neuroendocrine/carcinoid tumors. Cancer, 115: 4434–4441. doi: 10.1002/cncr.24498

Author Information

  1. 1

    Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio

  2. 2

    Arthur G. James and Richard J. Solove Cancer Hospital and Research Institute, Cancer Registry, Columbus, Ohio

  3. 3

    Department of Pathology, Ohio State University College of Medicine, Columbus, Ohio

  4. 4

    Department of Surgery, Division of Thoracic Surgery, Ohio State University College of Medicine, Columbus, Ohio

  1. †

    Fax: (614) 293-7529

*Department of Internal Medicine, Ohio State University College of Medicine, 320 West 10th Avenue, Columbus, OH 43210

Publication History

  1. Issue published online: 17 SEP 2009
  2. Article first published online: 26 JUN 2009
  3. Manuscript Accepted: 19 FEB 2009
  4. Manuscript Revised: 2 DEC 2008
  5. Manuscript Received: 10 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (218K)

References

  • 1
    Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79: 813-829.
    Direct Link:
  • 2
    Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999; 340: 858-868.
  • 3
    Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM. Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol. 2003; 10: 697-704.
  • 4
    Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007; 21: 15-31.
  • 5
    Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park). 2006; 20: 1537-1543; discussion 1544-1549.
  • 6
    Oberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist. 1998; 3: 339-345.
  • 7
    Aubry MC, Thomas CF Jr, Jett JR, Swensen SJ, Myers JL. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest. 2007; 131: 1635-1643.
  • 8
    Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001; 18: 1059-1068.
  • 9
    Travis W, Brambilla E, Muller-Hermelink H, Harris C. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
  • 10
    Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998; 22: 934-944.
  • 11
    Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972; 64: 413-421.
  • 12
    Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991; 15: 529-553.
  • 13
    Cerilli LA, Ritter JH, Mills SE, Wick MR. Neuroendocrine neoplasms of the lung. Am J Clin Pathol. 2001; 116( suppl): S65-S96.
  • 14
    Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40: 90-97.
  • 15
    Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007; 21: 163-172.
  • 16
    Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997; 6: 2285-2290.
  • 17
    Walch AK, Zitzelsberger HF, Aubele MM, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol. 1998; 153: 1089-1098.
  • 18
    Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001; 119: 1647-1651.
  • 19
    Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001; 12: 1295-1300.
  • 20
    Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006; 26: 41-57; discussion 57-58.
  • 21
    Jeung MY, Gasser B, Gangi A, et al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics. 2002; 22: 351-365.
  • 22
    Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998; 170: 1369-1373.
  • 23
    Kruger S, Buck AK, Blumstein NM, et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med. 2006; 260: 545-550.
    Direct Link:
  • 24
    Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007; 131: 255-260.
  • 25
    Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008; 26: 1489-1495.
  • 26
    Yellin A, Zwas ST, Rozenman J, Simansky DA, Goshen E. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J. 2005; 7: 712-716.
  • 27
    Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B, Westlin JE. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf). 2003; 59: 793-799.
    Direct Link:
  • 28
    Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006; 33: 1123-1133.
  • 29
    Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97: 934-959.
    Direct Link:
  • 30
    Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002; 37: 127-135.
  • 31
    Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest. 2001; 119: 14-18.
  • 32
    Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest. 2001; 119: 1143-1150.
  • 33
    Rea F, Rizzardi G, Zuin A, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg. 2007; 31: 186-191.
  • 34
    Ducrocq X, Thomas P, Massard G, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg. 1998; 65: 1410-1414.
  • 35
    Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004; 44: 213-220.
  • 36
    Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001; 12: 1383-1391.
  • 37
    Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008; 26: 1316-1323.
  • 38
    Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26: 4311-4318.
  • 39
    Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008; 26: 3403-3410.
  • 40
    Martini N, Zaman MB, Bains MS, et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J Thorac Cardiovasc Surg 1994; 107: 1-6; discussion 6-7.
  • 41
    Chakravarthy A, Abrams RA. Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer. 1995; 75: 1386-1390.
    Direct Link:
  • 42
    Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998; 29: 272-279.
View Full Article (HTML) Get PDF (218K)